

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of:

Inventor(s): Fang Wang, Chuck C. Xu, Baopei Xu &amp; Indira S. Pottebaum

For (title): HYPERBRANCHED FLUORINATED MULTIFUNCTIONAL  
ALCOHOLS AND DERIVATIVES1. **Type of Application**

- ☒ Utility  
☐ Design

The PTO did not receive the following  
 listed item(s) Assignment & signature

2. **Small Entity**

- ☒ Yes  
☐ No

3. **Benefit of Prior U.S. Application(s) Under 35 U.S.C. §120**

This application is a:

- ☐ Divisional  
☐ Continuation  
☐ Continuing Patent Application (CPA) under 37 C.F.R. §1.53(d)  
☐ Continuation-in-part (CIP),

and hereby claims benefit under 35 U.S.C. §120 to the following applications:

SERIAL NUMBER	FILING DATE

4. **Benefit of Non-U.S. Application Under 35 U.S.C. §119(a)-(d)**

This application claims priority under 35 U.S.C. §119(a)-(d) to the following foreign application(s) and/or inventor certificate(s):

COUNTRY	APPLN. NUMBER	FILING DATE
None		

Certified copy(ies) of the application(s) and/or inventor certificate's from which priority is claimed:

- ☐ is(are) attached;  
☐ will follow.

**CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10**

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on January 18, 2002

\_\_\_\_\_  
Name of Person Signing\_\_\_\_\_  
Signature of Person Signing

5. **Benefit of Provisional Application Under 35 U.S.C. §119(e)**

This application claims priority to the following provisional application(s):

SERIAL NUMBER	FILING DATE
60/264,200	January 25, 2001

6. **Papers Enclosed Which Are Required For Filing Date Under 37 C.F.R. §1.53**

29 Pages of Specification, including claims, abstract & coversheet

0 Sheets of Drawing

7. **Additional Papers Enclosed**

- ☒ Declaration and Power of Attorney  
☐ Preliminary Amendment  
☐ Information Disclosure Statement (37 CFR 1.98), Form PTO-1449 and a copy of each cited reference  
☒ Assignment and Form PTO-1595  
☐ Declaration of Biological Deposit  
☐ Submission of "Sequence Listing" computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequences.  
☐ Other \_\_\_\_\_

8. **Application Filing Fee Calculation**

A. ☒ Utility Application

FEE CALCULATION:

Total Claims: 21 - 20 = 1 × \$18 = \$ 18.00  
Independent Claims: 1 - 3 = 0 × \$80 = \$  
Basic Fee: .....\$758.00  
Multiple-Dependent-Claim Fee : .....\$

---

Total of the Above Calculations:..... \$758.00

- ☐ Amendment canceling extra claims enclosed.  
☐ Amendment deleting multiple dependencies enclosed.  
☐ Fee for extra claims is not being paid at this time.

B. ☐ Design application - \$320 \$  
Application Filing Fee Sub-Total ..... \$  
C. ☐ Less 50% reduction for small entity..... \$379.00  
D. ☐ Non-English Specification - \$130..... \$

**TOTAL FILING FEE ..... \$379.00**

9. **Payment**

- ☒ Enclosed
- ☒ Check in the amount of the Total Filing Fee set forth above.
- ☐ Charge Account No. 19-0079 in the amount of Total Filing Fee set forth above. A duplicate of this transmittal is attached.
- ☐ Not Enclosed

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 and 1.17 that may be required by this paper or any paper filed in connection with this Patent Application, or refund any overpayment to our Deposit Order Account No. 19-0079.

Respectfully submitted,

---

Arlene J. Powers  
Reg. No. 35,985  
Samuels, Gauthier & Stevens LLP  
225 Franklin Street, Suite 3300  
Boston, MA. 02110  
(617) 426-9180, Ext. 110

2025 RELEASE UNDER E.O. 14176

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)</b>	First Named Inventor		
	Title		
	Atty Docket Number		

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

**Burden Hour Statement:** This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner of Patents, Washington, DC 20231.